• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane: A Comprehensive Overview

The compound with CAS No 1339519-58-2, known as 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane, is a unique organic molecule that has garnered attention in the fields of organic chemistry and pharmacology. This compound is characterized by its spirocyclic structure, which combines a pyrrolidine ring and a six-membered azaspiro ring system. The integration of these structural elements contributes to its distinctive chemical properties and potential applications in drug design and development.

Spiro compounds have been of increasing interest in recent years due to their ability to create complex molecular architectures with diverse biological activities. The spiro system in 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane provides a rigid framework that can influence the molecule's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME). Recent studies have highlighted the importance of spiro compounds in medicinal chemistry, particularly in the design of bioactive molecules with improved potency and selectivity.

The pyrrolidine ring, a five-membered saturated heterocycle containing one nitrogen atom, is a common structural motif in many bioactive compounds. In this compound, the pyrrolidine group is attached via a methylene bridge to the spiro system. This arrangement enhances the molecule's flexibility while maintaining structural integrity. The nitrogen atom in the pyrrolidine ring can participate in hydrogen bonding, which is crucial for interactions with biological targets such as enzymes or receptors.

Recent advancements in synthetic methodologies have enabled the efficient construction of complex spiro systems like 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane. Researchers have employed various strategies, including ring-closing metathesis and intramolecular cyclization reactions, to assemble these structures with high precision. These techniques not only improve the yield of the synthesis but also allow for greater control over stereochemistry, which is essential for optimizing biological activity.

The azaspiro[2.5]octane core of this compound introduces an additional layer of complexity to its structure. The nitrogen atom within the spiro ring can act as a site for further functionalization, enabling the attachment of various substituents that may enhance its pharmacological properties. For instance, recent studies have explored the substitution of electron-withdrawing or donating groups on the nitrogen atom to modulate the molecule's electronic properties and improve its binding affinity to target proteins.

In terms of applications, 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane has shown potential as a scaffold for drug discovery efforts targeting various therapeutic areas. Its unique structure makes it an attractive candidate for designing molecules with anti-inflammatory, antiviral, or anticancer activities. For example, researchers have investigated its ability to inhibit key enzymes involved in inflammatory pathways, demonstrating promising results in preclinical models.

Moreover, computational studies using molecular docking and dynamics simulations have provided insights into how this compound interacts with biological targets at the molecular level. These studies have revealed that the spiro system plays a critical role in determining the molecule's binding mode and stability within target binding sites. Such findings underscore the importance of rational drug design approaches that leverage structural insights to optimize lead compounds.

Another area of interest lies in understanding the stereochemical effects on this compound's biological activity. Stereoisomerism can significantly influence how a molecule interacts with its target, and recent research has explored how different stereoisomers of 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane exhibit varying potencies and selectivities against specific targets.

In conclusion, 1-(Pyrrolidin-1-ylmethyl)-6-azaspiro[2.5]octane represents an intriguing example of how complex molecular architectures can be harnessed for drug discovery purposes. With its unique spiro system and functional groups contributing to diverse chemical properties, this compound continues to be a focal point for researchers seeking innovative solutions in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)